Half-Year 2022 Financial and Clinical Trials Update
2022: Upcoming newsflow
Pharma
Vabysmo in DME/nAMD
Ongoing and
Susvimo in nAMD
upcoming
launches
Polivy in 1L DLBCL
Lunsumio in 3L+ FL
tiragolumab + Tecentriq studies
NSCLC, Cervical, Esophageal cancer
Tecentriq adjuvant studies
HCC, neoadjuvant NSCLC
Late stage
pipeline
Venclexta in MM (t11;14)
read outs
Vabysmo in RVO
Susvimo in DMR/DR
gantenerumab in Alzheimer's
disease
cobas 5800 (FDA)
cobas pure (FDA)
cobas pulse (FDA)
Upcoming
launches
ElecsysⓇ IGRA
SARS-COV-2
Diagnostics
Real-time PCR molecular testing for low
volume labs
Serum work area analyzer for low-to-medium
sized labs
Device combining glucose meter and digital
platform
Measure T-cell release of IFN-y following
simulation by SARS-COV-2 specific antigens
Digital LightCycler Novel digital PCR platform
Elecsys
pTau/AB42 ratio
Gen2 CSF (FDA)
Detect amyloid disease & enable a broader
availability of testing for Alzheimer's Disease
Neuroscience
Oncology
Ophthalmology
Diagnostics
DME=diabetic macular edema; nAMD-neovascular age-related macular degeneration; DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; NSCLC=non-small cell lung cancer; HCC-hepatocellular carcinoma;
MM-multiple myeloma; RVO-retinal vein occlusion; CSF-cerebrospinal fluid; PCR-polymerase chain reaction
Roche
14View entire presentation